Epcoritamab + Rituximab
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Follicular Lymphoma
Conditions
Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult
Trial Timeline
Jun 21, 2023 → Feb 1, 2030
NCT ID
NCT05783609About Epcoritamab + Rituximab
Epcoritamab + Rituximab is a phase 2 stage product being developed by AbbVie for Follicular Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05783609. Target conditions include Follicular Lymphoma, Low Grade Non-Hodgkin's Lymphoma, Adult.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05783609 | Phase 2 | Recruiting |
Competing Products
20 competing products in Follicular Lymphoma